Payment overview · 2025
General Payments
$6,082.17
311 reported records · 26 companies
Healthcare provider profile · identity verified
James Darryl Adamo, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · ROSEVILLE, MI · NPI 1851311021
Verified facts
What the public records show
CMS Open Payments records show James Darryl Adamo, M.D. received $6,082.17 in general payments during 2025 across 311 reported records.
Neurocrine BioSciences, Inc. accounted for 11.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dyanavel Xr, Fanapt, Invega Sustenna, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Vraylar by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Invega Sustenna by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trintellix by this doctor in 2024.
Tris Pharma Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Dyanavel XR as an associated drug or biological on 17868 records involving 7985 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Dyanavel Xr by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $666.42 | 11.0% | 27 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $494.18 | 8.1% | 24 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $493.49 | 8.1% | 25 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $481.24 | 7.9% | 21 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $434.99 | 7.2% | 24 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $426.04 | 7.0% | 18 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $414.76 | 6.8% | 20 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $391.01 | 6.4% | 19 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $383.85 | 6.3% | 22 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $260.40 | 4.3% | 18 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $245.31 | 4.0% | 15 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $205.57 | 3.4% | 16 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $172.35 | 2.8% | 9 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $164.85 | 2.7% | 9 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $152.75 | 2.5% | 7 | 2025 |
| Validus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $150.46 | 2.5% | 11 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $97.89 | 1.6% | 4 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $75.57 | 1.2% | 5 | 2025 |
| Brainsway USA INC | Unresolved — no canonical attribution shown | $73.40 | 1.2% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $61.02 | 1.0% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $54.81 | 0.9% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.43 | 0.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.33 | 0.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.90 | 0.6% | 2 | 2025 |
| OWP Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.87 | 0.6% | 2 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $17.28 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $6,074.66 | 310 |
| Education | $7.51 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $666.42 | 27 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $493.49 | 25 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $481.24 | 21 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $437.23 | 22 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $414.76 | 20 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $400.96 | 18 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $391.01 | 19 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $383.85 | 22 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $260.40 | 18 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $224.20 | 11 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $222.78 | 13 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $210.79 | 13 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $205.57 | 16 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $164.85 | 9 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $152.75 | 7 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $145.78 | 6 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $138.27 | 5 | 2025 |
Source payment records
|
|||||
| EQUETRO Normalized: equetro |
Drug | Validus Pharmaceuticals LLC | $135.46 | 10 | 2025 |
Source payment records
|
|||||
| RALDESY Normalized: raldesy |
Drug | Validus Pharmaceuticals LLC | $114.48 | 9 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $97.89 | 4 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $75.57 | 5 | 2025 |
Source payment records
|
|||||
| Deep TMS System Normalized: deep tms system |
Device | Brainsway USA INC | $73.40 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $61.02 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $61.02 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $56.95 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.95 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $54.81 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $47.43 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.33 | 2 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $43.79 | 2 | 2025 |
Source payment records
|
|||||
| Subvenite Normalized: subvenite |
Drug | OWP Pharmaceuticals, Inc. | $35.87 | 2 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $22.53 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Adzenys XR-ODT Normalized: adzenys xr odt |
Drug | Neos Therapeutics, LP | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Dyanavel XR dyanavel xr |
2025 | Dyanavel Xr | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Tris Pharma Inc Exact reporting entity; no affiliate inference |
2025 | Dyanavel XR open payments reported associated product |
CMS Open Payments — General Payments 17868 supporting records · 7985 recipient NPIs · example record 1192249449 |
Dyanavel Xr · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 222 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 30 |
| Clonazepam | Clonazepam | 120 | 29 |
| Aripiprazole | Aripiprazole | 79 | 22 |
| Lorazepam | Lorazepam | 73 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 15 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 63 | 19 |
| Sertraline Hcl | Sertraline Hcl | 61 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 15 |
| Trazodone Hcl | Trazodone Hcl | 48 | 20 |
| Bupropion Xl | Bupropion Hcl | 39 | 14 |
| Vilazodone Hcl | Vilazodone Hcl | 38 | suppressed |
| Clozapine | Clozapine | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 11 |
| Doxepin Hcl | Doxepin Hcl | 34 | 13 |
| Vraylar | Cariprazine Hcl | 34 | suppressed |
| Olanzapine | Olanzapine | 33 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Amantadine | Amantadine Hcl | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Gabapentin | Gabapentin | 22 | suppressed |
| Perphenazine | Perphenazine | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 19 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Fetzima | Levomilnacipran Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Fanapt | Iloperidone | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Perphenazine-Amitriptyline | Perphenazine/Amitriptyline Hcl | 12 | suppressed |
| Dyanavel Xr | Amphetamine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,082.17 · 311 records | Neurocrine BioSciences, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, APLENZIN, ARISTADA, AUSTEDO XR, Adzenys XR-ODT, Auvelity, Azstarys, CAPLYTA, COBENFY, Deep TMS System, Dyanavel XR, EQUETRO, ERZOFRI EXTENDED-RELEASE, FANAPT, INGREZZA, INVEGA SUSTENNA, Jornay PM, LOREEV XR, LYBALVI, MOUNJARO, NUEDEXTA, QULIPTA, Qelbree, RALDESY, REXULTI, SPRAVATO, Subvenite, TRINTELLIX, UBRELVY, UZEDY, VRAYLAR, VYEPTI, WELLBUTRIN, Wegovy, ZEPBOUND, ZURZUVAE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dyanavel Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error